Mohit Chawla, MD, FCCP
Director, Interventional Pulmonology
Co-Director, Complex Airway Diseases
Robert P. Lee, MD
Director, Pleural Diseases
Assistant Director, Interventional Pulmonology
Nicholas Vander Els, MD, FCCP
Director, Pulmonary Function Laboratories
Memorial Sloan Kettering Cancer Center
New York, New York
Advanced interventional pulmonology (IP) techniques are revolutionizing the diagnosis and treatment of lung cancer. Minimally invasive bronchoscopy allows specialists to accurately diagnose and stage lung cancer and provide less-invasive therapeutic and palliative procedures for patients with malignant airway, pleural space, and lung parenchymal diseases.
Our IP experts collaborate with thoracic surgeons, interventional radiologists, radiation oncologists, and medical oncologists on the Thoracic Disease Management Team to develop the optimal diagnostic and treatment plan for each patient, often minimizing the need for multiple invasive procedures. We continue to develop and research new modalities, conduct clinical trials, and advance the field through our training fellowship and continuing medical education courses to train more subspecialists.
Minimally Invasive Procedures
Inserting instrumentation through a bronchoscope requires no incisions, providing patients with significant advantages compared with standard surgical or percutaneous options: less postoperative pain, faster recovery times, fewer complications, and shorter hospital stays. Many procedures are performed on an outpatient basis with low risk.
IP procedures can relieve symptoms in patients with advanced lung cancers, in some cases allowing them to be taken off ventilators or improving their quality of life so that they can receive additional cancer treatment that may extend survival.
MSK-Impact Tumor Genetic Profiling Assay
A significant benefit of advanced diagnostic bronchoscopy is that the technique can be used to obtain biopsies of sufficient size for use with MSK-IMPACT™ (Integrated Mutation Profiling of Actionable Cancer Targets), MSK’s genetic-profiling assay that uses high-throughput next-generation sequencing to look for alterations in more than 465 cancer-associated genes and other molecular biomarkers.
... to read the full story